Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Breast Cancer Gene (BRCA) Mutations Treatment Market Forecast: What Value Will The Market Reach By 2030?
The market size for breast cancer gene (brca) mutations treatment has experienced significant growth in recent years. This market is expected to expand from $5.01 billion in 2025 to $5.37 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.2%. The growth observed in the past can be attributed to several factors including limited awareness of brca mutations, restricted access to genetic testing services, a reliance on conventional chemotherapy, the increasing incidence of breast and ovarian cancer, and the gradual adoption of targeted therapies.
The breast cancer gene (brca) mutations treatment market size is anticipated to experience substantial growth over the next few years. It is projected to expand to $7 billion in 2030, driven by a compound annual growth rate (CAGR) of 6.9%. This expansion during the forecast period can be attributed to advancements in genomic sequencing technologies, the broader application of PARP inhibitor indications, increased investment in precision oncology, the rising adoption of combination therapies, and favorable reimbursement policies for genetic testing and targeted treatments. Key trends in the upcoming period include the growing uptake of genetic testing and early brca mutation screening, an increasing reliance on PARP inhibitors in targeted therapy, a stronger emphasis on preventive and risk-reduction treatment strategies, the continuous development of personalized and precision oncology approaches, and enhanced access to multimodal treatment options for brca-related cancers.
Get A Free Sample Report With In-Depth Market Insights:
Breast Cancer Gene (BRCA) Mutations Treatment Market Growth Drivers: What’s Behind The Acceleration?
The breast cancer gene (BRCA) mutation treatment market is anticipated to grow as a result of the increasing need for targeted therapies. Targeted therapies are medical interventions designed to specifically attack cancer cells by concentrating on genetic mutations or proteins that contribute to cancer growth. The escalating demand for these therapies is primarily due to their effectiveness in specifically targeting disease-causing cells or molecules while causing minimal damage to healthy tissues, leading to better treatment outcomes and fewer side effects compared to conventional treatments. Targeted therapies aid in the treatment of breast cancer gene (BRCA) mutations by offering precise medications that specifically address the genetic alterations driving the disease, thereby improving treatment results and reducing unnecessary side effects. For instance, in July 2023, according to a report from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, at the end of Q1 2023, there were 247 gene therapies in Phase II, which increased by 5% to reach 260 by the end of Q2 2023. Therefore, the growing demand for targeted therapies is propelling the expansion of the breast cancer gene (BRCA) mutation treatment market.
Breast Cancer Gene (BRCA) Mutations Treatment Market Segmentation: How Does The Market Break Down By Category?
The breast cancer gene (brca) mutations treatment market covered in this report is segmented –
1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy
2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
3) By Administration Route: Oral, Intravenous, Subcutaneous
4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics
Subsegments:
1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors
2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites
3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies
Breast Cancer Gene (BRCA) Mutations Treatment Market Competitive Overview And Top Companies
Major companies operating in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Genentech Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics
View The Full Breast Cancer Gene (BRCA) Mutations Treatment Market Report:
Breast Cancer Gene (BRCA) Mutations Treatment Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (brca) mutations treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model